Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Data Mining | 3 | 2020 | 45 | 2.010 |
Why?
|
| Genome-Wide Association Study | 4 | 2022 | 240 | 1.840 |
Why?
|
| Algorithms | 11 | 2022 | 1194 | 1.650 |
Why?
|
| Systems Biology | 3 | 2020 | 25 | 1.500 |
Why?
|
| Gene Ontology | 3 | 2020 | 31 | 1.500 |
Why?
|
| Software | 4 | 2022 | 418 | 1.420 |
Why?
|
| Molecular Sequence Annotation | 3 | 2020 | 14 | 1.330 |
Why?
|
| Genetic Pleiotropy | 3 | 2018 | 10 | 1.300 |
Why?
|
| Sequence Analysis, DNA | 4 | 2014 | 208 | 0.970 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2022 | 627 | 0.950 |
Why?
|
| Databases, Genetic | 4 | 2018 | 52 | 0.940 |
Why?
|
| Publications | 2 | 2020 | 17 | 0.940 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2013 | 52 | 0.900 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 94 | 0.850 |
Why?
|
| User-Computer Interface | 3 | 2019 | 230 | 0.830 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 320 | 0.800 |
Why?
|
| Genomics | 4 | 2018 | 167 | 0.740 |
Why?
|
| Transcription Factors | 4 | 2013 | 753 | 0.680 |
Why?
|
| Chromosome Mapping | 2 | 2017 | 188 | 0.680 |
Why?
|
| Models, Statistical | 4 | 2017 | 446 | 0.670 |
Why?
|
| Computer Simulation | 6 | 2022 | 705 | 0.660 |
Why?
|
| Models, Theoretical | 1 | 2020 | 384 | 0.610 |
Why?
|
| Computer Graphics | 1 | 2017 | 37 | 0.590 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 103 | 0.590 |
Why?
|
| Models, Genetic | 1 | 2017 | 161 | 0.570 |
Why?
|
| Binding Sites | 4 | 2013 | 631 | 0.560 |
Why?
|
| Appendix | 1 | 2016 | 9 | 0.560 |
Why?
|
| Appendiceal Neoplasms | 1 | 2016 | 9 | 0.560 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 267 | 0.550 |
Why?
|
| Appendicitis | 1 | 2016 | 55 | 0.530 |
Why?
|
| Bayes Theorem | 1 | 2017 | 303 | 0.530 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 24 | 0.510 |
Why?
|
| Databases, Factual | 1 | 2018 | 621 | 0.510 |
Why?
|
| Diphyllobothriasis | 1 | 2014 | 1 | 0.500 |
Why?
|
| Diphyllobothrium | 1 | 2014 | 1 | 0.500 |
Why?
|
| DNA, Helminth | 1 | 2014 | 1 | 0.500 |
Why?
|
| Electron Transport Complex IV | 1 | 2014 | 33 | 0.490 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 186 | 0.490 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 481 | 0.450 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2011 | 37 | 0.410 |
Why?
|
| Schools | 1 | 2012 | 156 | 0.400 |
Why?
|
| Social Environment | 1 | 2012 | 182 | 0.400 |
Why?
|
| Preventive Medicine | 2 | 2008 | 48 | 0.390 |
Why?
|
| Students | 1 | 2012 | 233 | 0.370 |
Why?
|
| Adolescent Behavior | 1 | 2012 | 264 | 0.370 |
Why?
|
| Humans | 28 | 2023 | 68525 | 0.350 |
Why?
|
| Authorship | 2 | 2008 | 18 | 0.340 |
Why?
|
| Neck | 1 | 2008 | 62 | 0.330 |
Why?
|
| Head | 1 | 2008 | 59 | 0.320 |
Why?
|
| Image Enhancement | 1 | 2008 | 143 | 0.310 |
Why?
|
| Community Networks | 1 | 2008 | 96 | 0.300 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1533 | 0.280 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 237 | 0.280 |
Why?
|
| Periodicals as Topic | 2 | 2008 | 158 | 0.280 |
Why?
|
| Republic of Korea | 3 | 2018 | 23 | 0.280 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 68 | 0.270 |
Why?
|
| Neoplasms | 4 | 2020 | 1660 | 0.270 |
Why?
|
| Computational Biology | 2 | 2019 | 190 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 2222 | 0.250 |
Why?
|
| Smoking | 1 | 2012 | 1449 | 0.240 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 498 | 0.240 |
Why?
|
| Escherichia coli Proteins | 2 | 2013 | 64 | 0.230 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 2077 | 0.230 |
Why?
|
| Heroin Dependence | 1 | 2022 | 23 | 0.220 |
Why?
|
| Interleukin-17 | 1 | 2022 | 62 | 0.210 |
Why?
|
| Exploratory Behavior | 1 | 2022 | 79 | 0.210 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 65 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 116 | 0.210 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 397 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 231 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 265 | 0.200 |
Why?
|
| Hepatitis C, Chronic | 1 | 2022 | 86 | 0.190 |
Why?
|
| Hepatitis C | 1 | 2022 | 114 | 0.190 |
Why?
|
| Base Sequence | 2 | 2014 | 1015 | 0.190 |
Why?
|
| Multigene Family | 1 | 2020 | 93 | 0.190 |
Why?
|
| Peptide Elongation Factor 2 | 1 | 2020 | 14 | 0.190 |
Why?
|
| Genotype | 3 | 2020 | 785 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 211 | 0.180 |
Why?
|
| Protein Biosynthesis | 1 | 2020 | 181 | 0.170 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2018 | 20 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 199 | 0.170 |
Why?
|
| Cilia | 1 | 2019 | 94 | 0.160 |
Why?
|
| Heart Valve Diseases | 1 | 2019 | 123 | 0.160 |
Why?
|
| Female | 12 | 2022 | 38015 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 299 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2020 | 212 | 0.160 |
Why?
|
| DNA Fingerprinting | 1 | 2017 | 11 | 0.160 |
Why?
|
| Aortic Valve | 1 | 2019 | 249 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2018 | 228 | 0.150 |
Why?
|
| Genes | 1 | 2017 | 86 | 0.150 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 177 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 114 | 0.150 |
Why?
|
| Neutrophils | 1 | 2018 | 204 | 0.150 |
Why?
|
| Programming Languages | 1 | 2017 | 16 | 0.150 |
Why?
|
| Australia | 1 | 2018 | 235 | 0.150 |
Why?
|
| Monte Carlo Method | 1 | 2017 | 124 | 0.150 |
Why?
|
| Biometry | 1 | 2017 | 72 | 0.150 |
Why?
|
| Markov Chains | 1 | 2017 | 133 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 244 | 0.150 |
Why?
|
| Poisson Distribution | 1 | 2016 | 84 | 0.140 |
Why?
|
| Internet | 1 | 2019 | 390 | 0.140 |
Why?
|
| Phenotype | 2 | 2021 | 946 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2018 | 714 | 0.140 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2017 | 172 | 0.140 |
Why?
|
| Phylogeny | 2 | 2014 | 196 | 0.140 |
Why?
|
| DNA, Bacterial | 2 | 2013 | 150 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 378 | 0.130 |
Why?
|
| Animals | 7 | 2022 | 20877 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2018 | 335 | 0.130 |
Why?
|
| Risk | 1 | 2016 | 563 | 0.130 |
Why?
|
| Genome | 2 | 2013 | 54 | 0.130 |
Why?
|
| Korea | 3 | 2009 | 13 | 0.120 |
Why?
|
| Praziquantel | 1 | 2014 | 1 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 508 | 0.120 |
Why?
|
| Middle Aged | 7 | 2021 | 21119 | 0.120 |
Why?
|
| Anthelmintics | 1 | 2014 | 8 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 329 | 0.120 |
Why?
|
| Male | 9 | 2022 | 37281 | 0.120 |
Why?
|
| Catheter Ablation | 1 | 2016 | 229 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 596 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 163 | 0.120 |
Why?
|
| Sphingolipids | 1 | 2017 | 337 | 0.120 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2013 | 4 | 0.120 |
Why?
|
| Biomarkers | 1 | 2019 | 1593 | 0.120 |
Why?
|
| Anaerobiosis | 1 | 2013 | 44 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 624 | 0.110 |
Why?
|
| Multilevel Analysis | 1 | 2012 | 7 | 0.110 |
Why?
|
| HIV Infections | 1 | 2020 | 775 | 0.110 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 1241 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2018 | 561 | 0.110 |
Why?
|
| Friends | 1 | 2012 | 33 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 334 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1139 | 0.110 |
Why?
|
| Mice | 4 | 2022 | 8472 | 0.100 |
Why?
|
| GATA1 Transcription Factor | 1 | 2011 | 19 | 0.100 |
Why?
|
| Base Composition | 1 | 2011 | 22 | 0.100 |
Why?
|
| STAT1 Transcription Factor | 1 | 2011 | 35 | 0.100 |
Why?
|
| Escherichia coli | 1 | 2013 | 368 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 614 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2011 | 48 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2011 | 237 | 0.100 |
Why?
|
| Pattern Recognition, Automated | 1 | 2011 | 70 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 2264 | 0.100 |
Why?
|
| Alphaproteobacteria | 1 | 2009 | 1 | 0.090 |
Why?
|
| Methylophilus | 1 | 2009 | 1 | 0.090 |
Why?
|
| Acanthamoeba | 1 | 2009 | 2 | 0.090 |
Why?
|
| Bacteroidetes | 1 | 2009 | 5 | 0.090 |
Why?
|
| Maxillofacial Development | 1 | 2009 | 1 | 0.090 |
Why?
|
| Quality of Life | 1 | 2018 | 1515 | 0.090 |
Why?
|
| Symbiosis | 1 | 2009 | 19 | 0.090 |
Why?
|
| Fresh Water | 1 | 2009 | 43 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 955 | 0.090 |
Why?
|
| Mouth | 1 | 2009 | 64 | 0.090 |
Why?
|
| Mitochondria | 1 | 2014 | 643 | 0.090 |
Why?
|
| Pharynx | 1 | 2009 | 89 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 93 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2009 | 295 | 0.080 |
Why?
|
| Sex Factors | 2 | 2021 | 1265 | 0.070 |
Why?
|
| Prognosis | 2 | 2023 | 2093 | 0.070 |
Why?
|
| Cerebral Angiography | 1 | 2006 | 151 | 0.070 |
Why?
|
| Young Adult | 2 | 2014 | 5708 | 0.060 |
Why?
|
| Catheterization | 1 | 2006 | 209 | 0.060 |
Why?
|
| Linear Models | 2 | 2021 | 521 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1753 | 0.060 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2023 | 7 | 0.060 |
Why?
|
| Loss of Heterozygosity | 1 | 2023 | 25 | 0.060 |
Why?
|
| CD11c Antigen | 1 | 2022 | 18 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 144 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 36 | 0.050 |
Why?
|
| Adolescent | 2 | 2012 | 8903 | 0.050 |
Why?
|
| Risk Factors | 1 | 2012 | 5719 | 0.050 |
Why?
|
| Toll-Like Receptors | 1 | 2022 | 56 | 0.050 |
Why?
|
| Heroin | 1 | 2022 | 49 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2022 | 90 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2021 | 14 | 0.050 |
Why?
|
| Genes, MHC Class II | 1 | 2021 | 29 | 0.050 |
Why?
|
| Estrogens | 1 | 2022 | 173 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2021 | 110 | 0.050 |
Why?
|
| Adult | 3 | 2016 | 21375 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2022 | 7264 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 80 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 67 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2022 | 201 | 0.050 |
Why?
|
| HIV | 1 | 2020 | 53 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 98 | 0.050 |
Why?
|
| Interleukins | 1 | 2020 | 79 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 73 | 0.050 |
Why?
|
| Viral Load | 1 | 2020 | 127 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 281 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 91 | 0.050 |
Why?
|
| Coculture Techniques | 1 | 2020 | 147 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2022 | 383 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2020 | 66 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2019 | 207 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 34 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.040 |
Why?
|
| Motor Activity | 1 | 2022 | 621 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 329 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 81 | 0.040 |
Why?
|
| Zebrafish Proteins | 1 | 2019 | 100 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2019 | 87 | 0.040 |
Why?
|
| Diphosphonates | 1 | 2018 | 39 | 0.040 |
Why?
|
| Zebrafish | 1 | 2019 | 187 | 0.040 |
Why?
|
| Bone Density Conservation Agents | 1 | 2018 | 43 | 0.040 |
Why?
|
| Gene Expression | 1 | 2021 | 770 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 215 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 100 | 0.040 |
Why?
|
| Mutation | 1 | 2023 | 1213 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 647 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 498 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 700 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1860 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1030 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Aged | 3 | 2021 | 14842 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 1055 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2018 | 7028 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1548 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1692 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 1849 | 0.030 |
Why?
|
| Rats | 1 | 2022 | 5300 | 0.030 |
Why?
|
| Genome, Bacterial | 1 | 2013 | 20 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2013 | 49 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 2790 | 0.030 |
Why?
|
| Contrast Media | 1 | 2016 | 594 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 2550 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3256 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 562 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 737 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2010 | 35 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2798 | 0.020 |
Why?
|
| Biostatistics | 1 | 2010 | 43 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2010 | 105 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2009 | 59 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2009 | 85 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 127 | 0.020 |
Why?
|
| Anthropometry | 1 | 2009 | 64 | 0.020 |
Why?
|
| Lymphoma | 1 | 2010 | 116 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 218 | 0.020 |
Why?
|
| Bibliometrics | 1 | 2008 | 25 | 0.020 |
Why?
|
| Radiography | 1 | 2009 | 572 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 4655 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 756 | 0.020 |
Why?
|
| Radial Artery | 1 | 2006 | 43 | 0.020 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2006 | 61 | 0.020 |
Why?
|
| Intracranial Hemorrhages | 1 | 2006 | 80 | 0.020 |
Why?
|
| Models, Biological | 1 | 2009 | 981 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2008 | 310 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2006 | 652 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 778 | 0.010 |
Why?
|
| Infant | 1 | 2009 | 2891 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 3185 | 0.010 |
Why?
|
| Child | 1 | 2009 | 6400 | 0.010 |
Why?
|